NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

Not Yet RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Complement 3 Glomerulopathy

This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

1. Adult patients (≥18 years).
2. Biopsy-confirmed C3G.
3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.

Exclusion criteria:

1\. Patients treated with iptacopan through an EAP for indications other than C3G.